<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;General principles for the diagnosis and management of asthma.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. General principles for the diagnosis and management of asthma. Southfield (MI): Michigan Quality Improvement Consortium; 2012 Jul. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. General principles for the diagnosis and management of asthma. Southfield (MI): Michigan Quality Improvement Consortium; 2010 Jul. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Allergic bronchopulmonary aspergillosis  (518.6); General physical examination  (89.7); Immunization for allergy  (99.12); Obesity, unspecified  (278.00); Obstructive sleep apnea (adult)(pediatric)  (327.23)"/><FieldValue Value="MSH: Administration, Inhalation ; Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Anti-Allergic Agents ; Anti-Asthmatic Agents ; Antibodies, Anti-Idiotypic ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Aspergillosis, Allergic Bronchopulmonary ; Asthma ; Blood Glucose Self-Monitoring ; Comorbidity ; Disease Management ; Drug Therapy ; Environment, Controlled ; Immunotherapy ; Influenza Vaccines ; Medical History Taking ; Nebulizers and Vaporizers ; Obesity ; Patient Care Planning ; Patient Education as Topic ; Peak Expiratory Flow Rate ; Physical Examination ; Pulmonary Medicine ; Referral and Consultation ; Respiratory Function Tests ; Rhinitis ; Risk Reduction Behavior ; Self Care ; Severity of Illness Index ; Sinusitis ; Sleep Apnea, Obstructive ; Spirometry "/><FieldValue Value="MTH: Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Allergen Immunotherapy ; Antibodies, Anti-Idiotypic ; Aspergillosis, Allergic Bronchopulmonary ; Asthma ; Asthma education ; Co-morbid conditions ; Disease Management ; follow-up ; Immunotherapy ; Influenza virus vaccine ; Inhalation Drug Administration ; Monoclonal Antibodies ; Obesity ; Patient education (procedure) ; Peak expiratory flow rate measurement ; Peak flow meter (device) ; Pharmacotherapy ; physical examination ; Pulmonary Medicine ; Respiratory Function Tests ; Rhinitis ; Self Monitoring ; Self-care interventions ; Sinusitis ; Sleep Apnea, Obstructive ; Spirometer (device) "/><FieldValue Value="PDQ: obesity "/><FieldValue Value="SNOMEDCT_US: Allergic bronchopulmonary aspergillosis  (37981002); Antiallergenic drugs  (135394005); Antiallergenic drugs  (372555007); Antiasthmatic agent  (360253007); Asthma  (195967001); Asthma clinical management plan  (412775002); Asthma education  (401135008); Asthma follow-up  (394701000); Asthma management  (406162001); Beta-adrenoceptor agonist  (349920008); Beta-adrenoceptor agonist  (373227004); Co-morbid conditions  (398192003); Corticoid preparation  (21568003); Corticoid preparation  (79440004); Drug therapy  (416608005); Harm avoidance behavior  (286661007); Hyposensitization to allergens  (182678001); Immunological therapy  (76334006); Influenza virus vaccine  (396425006); Influenza virus vaccine  (46233009); Inhaled drug administration  (243132000); Inhaler technique shown  (170613003); Measurement of respiratory function  (23426006); Monoclonal antibody  (49616005); Obesity  (414915002); Obesity  (414916001); Obstructive sleep apnea syndrome  (78275009); Omalizumab  (406442003); Omalizumab  (406443008); Patient education  (311401005); Peak expiratory flow rate monitoring  (401004000); Peak flow meter  (334990001); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Pulmonary medicine  (418112009); Rhinitis  (70076002); Self-care interventions  (384758001); Self-monitoring  (310858007); Self-monitoring  (441211000124106); Self-monitoring of blood glucose  (308113006); Sinusitis  (36971009); Spirometer  (303501006); Spirometry  (127783003); Step up change in asthma management plan  (390877003)"/><FieldValue Value="SPN: METER, PEAK FLOW, SPIROMETRY "/><FieldValue Value="UMD: Analyzers, Point-of-Care, Whole Blood, Glucose  (16-488); Flowmeters, Gas, Respiratory, Peak Expiratory Flow  (15-965); Inhalers, Aerosol  (12-128); Spirometers  (13-674)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Asthma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Allergy and Immunology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Pediatrics" /><FieldValue Value="Pulmonary Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Plans" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;To achieve significant, measurable improvements in the management of asthma through the development and implementation of common evidence-based clinical practice guidelines&lt;/li&gt;&#xD;&#xA;&lt;li&gt;To design concise guidelines that are focused on key management components of asthma to improve outcomes&lt;/li&gt;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Children and adults with the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Wheezing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;History of cough (worse particularly at night), recurrent wheeze, recurrent difficulty in breathing, recurrent chest tightness &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptoms occur or worsen in the presence of exercise, viral infection, inhalant allergens, irritants, changes in weather, strong emotional expression (laughing or crying hard), stress, menstrual cycles &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptoms occur or worsen at night, awakening the patient&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Detailed medical history, physical examination, and symptom assessment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of asthma severity and asthma control &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Spirometry &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Development of written asthma action plan &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Self-management education &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Control environmental factors&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treat comorbid conditions&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Allergen immunotherapy&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Omalizumab&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inactivated influenza vaccine &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inhaled corticosteroids (ICS)&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Long-acting beta agonists (LABAs) (only under specific conditions)&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral to asthma specialist&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Michigan Quality Improvement Consortium (MQIC) health care analyst conducts a search of current literature in support of the guideline topic. Computer database searches are used to identify published studies, existing protocols and/or national guidelines on the selected topic developed by organizations such as the American Diabetes Association, American Heart Association, American Academy of Pediatrics, etc. If available, clinical practice guidelines from participating MQIC health plans and Michigan health systems are also used to develop a framework for the new guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For the current update of the guideline the National Heart, Lung, and Blood Institute (NHLBI); PubMed; and Google databases were searched from 2007 to 2012. Specific terms used were: asthma exacerbation, asthma action plans, asthma severity assessment, LABA children, asthma follow-up care.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational studies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Using information obtained from literature searches and available health plan guidelines on the designated topic, the Michigan Quality Improvement Consortium (MQIC) health care analyst prepares a draft guideline to be reviewed by the Medical Directors' Committee at one of their scheduled meetings. Priority is given to recommendations with [A] and [B] levels of evidence (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The initial draft guideline is reviewed, evaluated, and revised by the committee resulting in draft two of the guideline. Additionally, the Michigan Academy of Family Physicians participates in guideline development at the onset of the process and throughout the guideline development procedure. The MQIC guideline feedback form and draft two of the guideline are distributed to the medical directors, as well as the MQIC measurement and implementation group members, for review and comments. Feedback from members is collected by the MQIC health care analyst and prepared for review by the Medical Directors' Committee at their next scheduled meeting. The review, evaluation, and revision process with several iterations of the guideline may be repeated over several meetings before consensus is reached on a final draft guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;When consensus is reached on the final draft guideline, the medical directors approve the guideline for external distribution to practitioners with review and comments requested via the Michigan Quality Improvement Consortium (MQIC) health plans (health care analyst distributes final draft to Medical Directors' Committee, measurement and implementation groups to solicit feedback).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst also forwards the approved guideline draft to appropriate state medical specialty societies for their input. After all feedback is received from external reviews, it is presented for discussion at the next scheduled committee meeting. Based on feedback, subsequent guideline review, evaluation, and revision may be required prior to final guideline approval.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC Medical Directors approved this updated guideline in July 2012.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The level of evidence grades (&lt;strong&gt;A-D&lt;/strong&gt;) are provided for the most significant recommendations and are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diagnosis and Management Goals&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Detailed medical history and physical exam to determine that symptoms of recurrent episodes of airflow obstruction are present. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use spirometry* in all patients &amp;ge;5 years of age to determine that airway obstruction is at least partially reversible &lt;strong&gt;[C]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider alternative causes of airway obstruction. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Goals of therapy are to achieve control by [A]&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Reducing impairment (prevent chronic symptoms, minimize need for rescue therapy with short-acting beta&lt;sub&gt;2&lt;/sub&gt;-agonists [SABAs], maintain near-normal lung function and activity levels). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reducing risk (prevent exacerbations, minimize need for emergency care or hospitalization, prevent loss of lung function or prevent reduced lung growth in children, have minimal or no adverse effects of therapy). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Assessment and Monitoring&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assess asthma severity to initiate therapy. (Use severity classification chart, assessing both domains of impairment &lt;strong&gt;[B]&lt;/strong&gt; and risk &lt;strong&gt;[C]&lt;/strong&gt; to determine initial treatment.) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess asthma control to monitor and adjust therapy &lt;strong&gt;[B]&lt;/strong&gt;. (Use asthma control chart, assessing both domains of impairment and risk to determine if therapy should be maintained or adjusted. Step up if necessary; step down if possible.) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obtain spirometry* to confirm control, and at least every 1-2 years &lt;strong&gt;[B]&lt;/strong&gt;, more frequently for not well-controlled asthma. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Schedule follow-up care: consider scheduling patients within 1 week, or sooner, if acute exacerbation; at 2- to 6-week intervals while gaining control&lt;strong&gt; [D]&lt;/strong&gt;; at 1- to 6-month intervals, depending on step of care required or duration of control, to monitor if sufficient control is maintained; at 3-month interval if a step-down in therapy is anticipated &lt;strong&gt;[D]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess asthma control, medication technique, written asthma action plan, patient adherence and concerns at every visit. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Spirometry = Forced expiratory volume in one second (FEV&lt;sub&gt;1&lt;/sub&gt;), FEV&lt;sub&gt;6&lt;/sub&gt;, forced vital capacity (FVC), FEV&lt;sub&gt;1&lt;/sub&gt;/FVC&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Education&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Provide self-management education &lt;strong&gt;[A]&lt;/strong&gt;. Teach and reinforce: self-monitoring to assess control and signs of worsening asthma (either symptom or peak flow monitoring) &lt;strong&gt;[B]&lt;/strong&gt;; using written asthma action plan (review differences between long-term control and quick-relief medication); taking medication correctly (inhaler technique and use of devices); avoiding environmental and occupational factors that worsen asthma. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tailor education to literacy level of patient; integrate education into all points of care; appreciate potential role of patient's cultural beliefs and practices in asthma management &lt;strong&gt;[C]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Develop written action plan in partnership with patient &lt;strong&gt;[B]&lt;/strong&gt;. Update annually, more frequently if needed. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Control Environmental Factors and Comorbid Conditions&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Recommend measures to control exposures to allergens and pollutants or irritants that make asthma worse &lt;strong&gt;[A]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider allergen immunotherapy for patients with persistent asthma and when there is clear evidence of a relationship between symptoms and exposure to an allergen to which the patient is sensitive &lt;strong&gt;[B]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treat comorbid conditions (e.g., allergic bronchopulmonary aspergillosis &lt;strong&gt;[A]&lt;/strong&gt;, gastroesophageal reflux &lt;strong&gt;[B]&lt;/strong&gt;, obesity &lt;strong&gt;[B]&lt;/strong&gt;, obstructive sleep apnea &lt;strong&gt;[D]&lt;/strong&gt;, rhinitis and sinusitis &lt;strong&gt;[B]&lt;/strong&gt;, chronic stress or depression &lt;strong&gt;[D]&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inactivated influenza vaccine for all patients over 6 months of age &lt;strong&gt;[A]&lt;/strong&gt; unless contraindicated. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Medications&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Initial treatment should be based on the severity of asthma, both impairment and risk. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inhaled corticosteroids (ICS) are the most effective long-term control therapy &lt;strong&gt;[A]&lt;/strong&gt;. Optimize ICS use before advancing to other therapies. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Re-evaluate in 2 to 6 weeks for control. Modify treatment based on level of control. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider step down if well-controlled for 3 months. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Warning for use of long-acting beta-agonists (LABAs). See Black Box Warning:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Do not use LABA as monotherapy. Use only with an asthma controller such as inhaled corticosteroids (preferably combination product for children). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use for the shortest duration possible. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Only use if not controlled on other drugs. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pediatric and adolescent patients who require the addition of a LABA to an inhaled corticosteroid should use a combination product containing both. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Referral&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Refer to an asthma specialist for consultation or co-management if there are difficulties achieving or maintaining control (see age-specific guidelines); immunotherapy or omalizumab is considered; additional testing is indicated; or if the patient required 2 bursts of oral corticosteroids in the past year or a hospitalization &lt;strong&gt;[D]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational studies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence is provided for the most significant recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline is based on the 2007 National Asthma Education and Prevention Program Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma, National Heart, Lung and Blood Institute (&lt;a href=&quot;http://www.nhlbi.nih.gov/&quot; title=&quot;NHLBI Web site&quot; target=&quot;_blank&quot;&gt;www.nhlbi.nih.gov&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Through a collaborative approach to developing and implementing common clinical practice guidelines and performance measures for the diagnosis and management of asthma, Michigan health plans will achieve consistent delivery of evidence-based services and better health outcomes. This approach also will augment the practice environment for physicians by reducing the administrative burdens imposed by compliance with diverse health plan guidelines and associated requirements.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;There is a Black Box Warning for the use of long-acting beta-agonists (LABAs).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline lists core management steps. Individual patient considerations and advances in medical science may supersede or modify these recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Approved Michigan Quality Improvement Consortium (MQIC) guidelines are disseminated through email, U.S. mail, and websites.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst prepares approved guidelines for distribution. Portable Document Format (PDF) versions of the guidelines are used for distribution.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst distributes approved guidelines to MQIC membership via email.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to website vendor to post approved guidelines to MQIC Web site (&lt;a href=&quot;http://www.mqic.org&quot; title=&quot;MQIC Web site&quot;&gt;www.mqic.org&lt;/a&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst completes an annual statewide postcard mailing to physicians in all areas of medicine including primary care and specialties. The postcard provides the complete list of MQIC guidelines and includes which guidelines have been recently revised, which are coming up for revision, and any new published guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The statewide mailing list is derived from the Blue Cross Blue Shield of Michigan (BCBSM) provider database. Approximately 95% of the state's M.D.'s and 96% of the state's D.O.'s are included in the database.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to the National Guideline Clearinghouse (NGC) to post approved guidelines to the NGC Web site (&lt;a href=&quot;http://www.guideline.gov&quot; title=&quot;NGC Web site&quot; target=&quot;_blank&quot;&gt;www.guideline.gov&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Resources" /><FieldValue Value="Tool Kits" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. General principles for the diagnosis and management of asthma. Southfield (MI): Michigan Quality Improvement Consortium; 2012 Jul. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is based on the 2007 National Asthma Education and Prevention Program Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma, National Heart, Lung and Blood Institute (&lt;a href=&quot;http://www.nhlbi.nih.gov&quot; title=&quot;NHLBI Web site&quot; target=&quot;_blank&quot;&gt;www.nhlbi.nih.gov&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2008 Jul (revised 2012 Jul)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Michigan Quality Improvement Consortium - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium Medical Director's Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Physician representatives from the 13 participating Michigan Quality Improvement Consortium health plans, Michigan State Medical Society, Michigan Osteopathic Association, Michigan Association of Health Plans, Michigan Department of Community Health, Michigan Peer Review Organization, and the University of Michigan Health System&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Standard disclosure is requested from all individuals participating in the Michigan Quality Improvement Consortium (MQIC) guideline development process, including those parties who are solicited for guideline feedback (e.g., health plans, medical specialty societies). Additionally, members of the MQIC Medical Directors' Committee are asked to disclose all commercial relationships.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. General principles for the diagnosis and management of asthma. Southfield (MI): Michigan Quality Improvement Consortium; 2010 Jul. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.mqic.org/pdf/mqic_general_principles_for_the_diagnosis_and_management_of_asthma_cpg.pdf&quot; title=&quot;Michigan Quality Improvement Consortium Web site&quot;&gt;Michigan Quality Improvement Consortium Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Asthma action plan. National Institute of Health; 2007 Apr. 2 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://mqic.org/physician-tools.htm&quot; title=&quot;Michigan Quality Improvement Consortium (MQIC) Web site&quot;&gt;Michigan Quality Improvement Consortium (MQIC) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Asthma control plan for child. Electronic copies: Available in PDF from the &lt;a href=&quot;http://mqic.org/physician-tools.htm&quot; title=&quot;Michigan Quality Improvement Consortium (MQIC) Web site&quot;&gt;MQIC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Asthma Guideline Implementation Steps &amp;amp; Tools (GIST). Asthma Initiative of Michigan. Available from the &lt;a href=&quot;http://mqic.org/physician-tools.htm&quot; title=&quot;Michigan Quality Improvement Consortium (MQIC) Web site&quot;&gt;MQIC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inhaled quick relief and controller medications. University of Michigan; 2011 Jan. 2 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://mqic.org/physician-tools.htm&quot; title=&quot;Michigan Quality Improvement Consortium (MQIC) Web site&quot;&gt;MQIC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Michigan Asthma Resource Kit (MARK). Asthma Initiative of Michigan. Available from the &lt;a href=&quot;http://mqic.org/physician-tools.htm&quot; title=&quot;Michigan Quality Improvement Consortium (MQIC) Web site&quot;&gt;MQIC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on November 24, 2008. The information was verified by the guideline developer on December 4, 2008. This NGC summary was updated by ECRI Institute on January 18, 2010. The updated information was verified by the guideline developer on February 14, 2011. This NGC summary was updated by ECRI Institute on January 4, 2013. The updated information was verified by the guideline developer on February 7, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which may be reproduced with the citation developed by the Michigan Quality Improvement Consortium.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
